Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The Latin America peripheral T-cell lymphoma market was valued at USD 67.89 Million in 2025 and is expected to grow at a CAGR of 4.10%, reaching USD 101.46 Million by 2035. The market growth is driven by significant improvements in treatment outcomes, increased awareness, and early diagnosis, which are expanding patient access to advanced peripheral T-cell lymphoma therapies.
Q1 2026 Market Updates
The Latin America peripheral T-cell lymphoma (PTCL) treatment market is navigating a period of compounded uncertainty as the ongoing Iran-US-Israel conflict disrupts the global pharmaceutical supply chain. PTCL remains a rare and aggressive group of non-Hodgkin lymphomas with limited treatment options in the region, where CHOP-based chemotherapy continues to serve as the standard first-line therapy. Access to newer targeted agents and clinical trials has historically been constrained across Latin American healthcare systems, and the war is now amplifying these challenges by disrupting the flow of oncology drugs and critical raw materials.
The closure of the Strait of Hormuz has reduced commercial shipping through the waterway by roughly 90 percent, forcing pharmaceutical companies to reroute shipments of active pharmaceutical ingredients (APIs) and finished medicines. India, which supplies a significant share of generic oncology drugs to Latin American markets, relies heavily on Gulf shipping lanes for exports. Air cargo capacity through Gulf hubs in Dubai, Abu Dhabi, and Doha has dropped by 79 percent following airport closures, while air freight rates from Asia have surged by over 45 percent. These disruptions are particularly concerning for biosimilar cancer treatments and temperature-sensitive drugs that depend on cold-chain logistics, as rerouting adds transit time and increases the risk of degradation.
For Latin America, the downstream effects are becoming increasingly visible. Countries such as Brazil, Mexico, Argentina, and Colombia, which import a substantial portion of their oncology medications, face the prospect of supply delays and cost escalations. The region already contends with heterogeneous access to advanced PTCL therapies, with urban centers in Brazil and Argentina offering guideline-based treatments while peripheral regions lag behind. Rising input costs for chemotherapy agents, monoclonal antibodies, and stem cell transplant-related drugs could further widen these disparities, particularly in lower-income countries with limited public health budgets.
A 2025 study published in The Lancet Haematology examining PTCL outcomes across multiple Latin American countries highlighted the urgent need for improved diagnostic infrastructure and expanded access to novel therapies. The war now threatens to stall progress on both fronts, as governments redirect fiscal resources toward energy security and inflation management. Marine insurance premiums have risen by over 300 percent according to Lloyd is of London, and these costs are being passed along the supply chain, ultimately raising the price of imported pharmaceuticals for Latin American health systems.
Key Takeaways
Government: Latin American governments face mounting pressure to secure alternative pharmaceutical supply routes and build strategic drug stockpiles as Middle East shipping disruptions threaten oncology drug availability. Regulatory agencies in Brazil and Mexico are expediting emergency import authorizations, while regional health ministries are coordinating with PAHO to assess vulnerability in cancer treatment supply chains.
Market: The PTCL treatment market in Latin America is experiencing upward cost pressure as API prices rise and logistics expenses surge due to Strait of Hormuz disruptions. Generic oncology drug suppliers are renegotiating contracts to account for 45 percent higher air freight costs and extended delivery timelines, while biosimilar manufacturers face cold-chain integrity risks from rerouted shipments.
Procurement: Hospital procurement teams across Latin America are shifting to multi-source supplier strategies and increasing safety stock levels for critical chemotherapy regimens. Procurement cycles for PTCL drugs including pralatrexate, romidepsin, and belinostat have extended by two to four weeks, prompting health systems to explore direct sourcing agreements with manufacturers outside traditional Gulf-routed supply chains.
Key Market Trends and Insights
- By disease type, PTCL–NOS is likely to lead the market, accounting for about 30% of revenue share in the historical period.
- By treatment type, chemotherapy is expected to remain the most widely used option.
- By route of administration, oral therapies are anticipated to be preferred because of convenience and better patient adherence.
- By end user, hospitals are likely to continue as the primary segment for PTCL treatments.
- By distribution channel, hospital pharmacies are expected to dominate due to direct access to patients.
Market Size and Forecast
- Market Size (2025): USD 67.89 Million
- Projected Market Size (2035): USD 101.46 Million
- CAGR (2026-2035): 4.10%
2025
Base Year
2019-2025
Historical Period
2026-2035
Forecast Period
-
In Latin America, rising awareness of relapse challenges in PTCL highlighted the importance of cancer research, driving demand for advanced therapies and improving patient outcomes across the region.
-
In the PTCL market, new clinical trials emphasized innovation and growth in cancer research, accelerating the development of targeted and effective treatment options across Latin America.
-
In the region, the focus on oral and targeted therapies for PTCL strengthened the role of cancer research, fostering the adoption of innovative treatment approaches.
Compound Annual Growth Rate
4.1%
Value in USD Million
2026-2035
*this image is indicative*
Latin America Peripheral T-Cell Lymphoma Market Overview
The market is witnessing steady growth, driven by rising awareness, early diagnosis, and advancements in targeted therapies. PTCL–NOS is expected to dominate the market due to its high prevalence, while chemotherapy and emerging immunotherapies remain key treatment options. Brazil leads the regional market with a strong healthcare infrastructure and active clinical research, followed by Mexico. Hospitals and hospital pharmacies continue to serve as primary end users and distribution channels. Increasing investment in innovative therapies, clinical trials, and patient-centric treatment approaches is shaping the market, making Latin America a significant growth hub for peripheral T-cell lymphoma treatment.
Latin America Peripheral T-Cell Lymphoma Market Growth Drivers
Rising Advancements in Treatment Outcomes Accelerating the Market Value
Significant improvements in treatment outcomes are expected to drive growth in the market, as more effective therapies increase survival rates and patient quality of life. In recent years, increased awareness and early diagnosis have also helped identify patients who can benefit from advanced therapies, further supporting market expansion. For instance, in October 2023, the T-Cell Brazil Project found that although relapse remains a challenge, salvage therapies such as hematopoietic stem cell transplantation offer significant benefits. This emphasis on advanced lymphoma treatment options is boosting market demand, attracting investments, and encouraging innovation across the region’s healthcare landscape.
Increasing Awareness and Clinical Insights Driving Growth in the Latin America Peripheral T-Cell Lymphoma Market
Enhanced understanding of disease patterns and patient outcomes is expected to be a growth driver in the market, as this knowledge helps healthcare providers deliver more targeted and effective therapies. For example, in April 2025, PubMed reported a study that aimed to analyze clinical characteristics, treatment responses, and survival outcomes of patients across Latin America. The study was performed as a retrospective analysis of medical records from multiple centers in the region. The findings concluded that recognizing regional disease trends and tailoring treatment strategies, especially for aggressive cases, can significantly improve patient outcomes. This focus on advanced lymphoma treatment options is driving investment, research, and wider access to innovative therapies in the market.
Latin America Peripheral T-Cell Lymphoma Market Trends
The market is witnessing several emerging trends, including the rise of innovative therapies, expanding clinical trial activity, and growing adoption of targeted treatments for peripheral T-cell lymphoma.
Emerging Clinical Trial Momentum Bolstering the Latin America Peripheral T‑Cell Lymphoma Market Expansion
The increasing focus on innovative therapies is shaping the market. For instance, in April 2025, Yingli Pharma secured FDA approval to launch a global Phase III trial of linperlisib for relapsed/refractory peripheral T‑cell lymphoma. This trial is particularly significant as it targets patients who have limited treatment options, offering hope for improved outcomes. This trend reflects growing confidence in novel cancer therapy options. By comparing linperlisib with standard care, the study highlights an industry-wide shift toward more targeted and potentially effective treatments. Such trial activity is helping to galvanize investment, accelerate drug development, and improve access to cutting‑edge therapies in Latin America.
Latin America Peripheral T-Cell Lymphoma Market Share
PTCL–NOS Expected to Lead the Market Share by Disease Type
PTCL–NOS is anticipated to lead the market due to its higher prevalence and challenging treatment landscape, driving demand for advanced therapies. Growing awareness, improved diagnosis, and the introduction of targeted lymphoma treatment options are accelerating adoption and fueling market growth. The segment’s dominance is likely to encourage further investment in research and innovative therapies. Other segments include Angioimmunoblastic T-cell lymphoma (AITL), Anaplastic large cell lymphoma (ALCL) (ALK-positive ALCL), Extranodal NK/T-cell lymphoma (ENKTL), and other peripheral T-cell subtypes.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Latin America Peripheral T-Cell Lymphoma Market Analysis by Region
Brazil is expected to lead the market due to its high patient population and well-established healthcare infrastructure supporting advanced treatments. Increasing government initiatives and investments in cancer care are further strengthening Brazil’s position as a key market driver. The country has also been active in clinical research and the adoption of innovative lymphoma treatment options, contributing significantly to regional growth. Mexico is expected to hold the second-largest share, driven by improving healthcare access and increasing awareness. Other key markets include Argentina, Colombia, Chile, Peru, Bolivia, Uruguay, Paraguay, Panama, and additional Latin American countries, all gradually expanding their role in the market.
Leading Players in the Latin America Peripheral T-Cell Lymphoma Market
The key features of the market report comprise funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Bristol Myers Squibb Company
Founded in 1887 and headquartered in Princeton, New Jersey, USA, Bristol Myers Squibb (BMS) is a global biopharmaceutical leader focusing on oncology and immunotherapy. Over the years, BMS has built a strong pipeline for rare blood cancers, ensuring patients have access to advanced therapies. In the peripheral T‑cell lymphoma (PTCL) space, BMS developed romidepsin (Istodax®) for relapsed/refractory PTCL, demonstrating its commitment to innovation. The company also invests heavily in CAR‑T cell therapy research, driving growth in lymphoma treatment options and shaping future therapeutic strategies. These efforts reinforce BMS’s position as a leading innovator in the PTCL therapeutic landscape.
F. Hoffmann La Roche Ltd.
Founded in 1896 and based in Basel, Switzerland, Roche is a pioneer in diagnostics and oncology. The company combines research and technology to deliver precision medicine, improving patient care globally. While Roche’s PTCL-specific therapies are limited, its immuno-oncology expertise and diagnostic tools help shape the broader cancer therapy landscape, supporting early diagnosis and targeted treatments. Roche’s continued investment in oncology research strengthens its role in advancing treatments for rare lymphoma subtypes across multiple sectors. This integrated diagnostics-driven approach supports Roche’s long-term influence in the evolving PTCL market.
Novartis AG
Novartis was formed in 1996 and is headquartered in Basel, Switzerland. As a global leader in oncology, Novartis has been pioneering CAR‑T cell therapy, transforming treatment options for hematologic cancers. The company also emphasizes research in emerging therapies and innovative treatment platforms. Although its current PTCL portfolio is limited, Novartis’ cellular therapy expertise and broad cancer-treatment strategy position it to contribute significantly to peripheral T‑cell lymphoma research, supporting better patient outcomes and long-term growth in the market. Consequently, Novartis remains strategically positioned to expand its role in next-generation PTCL therapies.
Takeda Pharmaceutical Company Limited
Takeda, founded in 1781 and headquartered in Tokyo, Japan, is a global pharmaceutical company with a strong focus on oncology. The company has consistently expanded its oncology portfolio to meet evolving patient needs. Takeda markets brentuximab vedotin (Adcetris®) for CD30-positive T-cell lymphomas and continues to invest in rare hematologic malignancies. Its commitment to innovative lymphoma treatment options and targeted therapies improves patient access and outcomes, making Takeda a key contributor to the growth of the market worldwide. These initiatives solidify Takeda’s role as a major driver of innovation in the PTCL treatment market.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players include Merck & Co., Inc., Pfizer Inc., AbbVie Inc., Gilead Sciences, Inc., Astellas Pharma Inc., and Johnson & Johnson Innovative Medicine.
Latin America Peripheral T-Cell Lymphoma Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
- PTCL–NOS
- Angioimmunoblastic T-cell lymphoma (AITL)
- Anaplastic large cell lymphoma (ALCL) (ALK-positive ALCL)
- Extranodal NK/T-cell lymphoma (ENKTL)
- Other peripheral T-cell subtypes
Market Breakup by Treatment Types
- Chemotherapy
- Monoclonal Antibodies / ADCs
- Epigenetic Agents / HDAC InhibitorsRomidepsin
- Belinostat
- Romidepsin
- Antifolates / Cytotoxic Agents
- Hypomethylating Agents / Combination Epigenetic Therapy
- Targeted Small Molecules / Kinase Inhibitors
- Immunotherapies
- Stem Cell Transplant / Cellular Therapies
- Radiation Therapy / Supportive Care
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by End User
- Hospitals
- Cancer Institutes
- Homecare Settings
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Specialty Cancer Clinics
- Research and Academic Institutes
- Others
Market Breakup by Country
- Brazil
- Mexico
- Argentina
- Others
Key Questions Answered in the Latin America Peripheral T-Cell Lymphoma Market Report
- What was the Latin America peripheral T-cell lymphoma market value in 2025?
- What is the Latin America peripheral T-cell lymphoma market forecast outlook for 2026-2035?
- What is the market breakup based on disease type?
- What is the market segmentation based on treatment types?
- What is the market segmentation based on route of administration?
- What is the market breakup based on the end user?
- What is the market segmentation based on the distribution channel?
- What are the major factors aiding the Latin America peripheral T-cell lymphoma market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major Latin America peripheral T-cell lymphoma market trends?
- Which disease type is expected to dominate the market segment?
- Which treatment types are projected to lead the market segment?
- Which route of administration is likely to dominate the market segment?
- Which end user is likely to dominate the market segment?
- Which distribution channel is likely to dominate the market segment?
- Who are the key players involved in the Latin America peripheral T-cell lymphoma market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Pricing Plans
Upto 15% Off
USD
-
$2699 $2429
-
$4299 $3869
-
$5799 $4949
-
$6999 $5949
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Treatment Types |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share